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Huntington’s disease (HD) is a fatal neurodegenerative disorder, caused by a
polyglutamine expansion in the huntingtin protein (HTT). HD has a peripheral component
to its pathology: skeletal muscles are severely affected, leading to atrophy, and
malfunction in both pre-clinical and clinical settings. We previously used two symptomatic
HD mouse models to demonstrate the impairment of the contractile characteristics
of the hind limb muscles, which was accompanied by a significant loss of function
of motor units. The mice displayed a significant reduction in muscle force, likely
because of deteriorations in energy metabolism, decreased oxidation, and altered purine
metabolism. There is growing evidence suggesting that HD-related skeletal muscle
malfunction might be partially or completely independent of CNS degeneration. The
pathology might arise from mutant HTT within muscle (loss or gain of function). Hence, it
is vital to identify novel peripheral biomarkers that will reflect HD skeletal muscle atrophy.
Thesewill be important for upcoming clinical trials that may target HD peripherally. In order
to identify potential biomarkers that might reflect muscle metabolic changes, we used
qPCR to validate key gene transcripts in different skeletal muscle types. Consequently,
we report a number of transcript alterations that are linked to HD muscle pathology.
Keywords: Huntington’s disease, skeletal muscle atrophy, purine metabolism, transcriptional deregulation,
biomarkers, mouse models
INTRODUCTION
Skeletal muscle loss and dysfunction are often associated with aging but are also found in many
chronic diseases with diverse etiologies (Vinciguerra et al., 2010). The list includes Huntington’s
disease (HD), which is amonogenic neurodegenerative disorder caused by a CAG-repeat expansion
within the huntingtin gene (HTT). The expansion mutation is found in Exon-1 and translates into
a polyglutamine stretch (polyQ) in HTT protein, which alters function (for a recent review see
Zielonka et al., 2015). To date, the best functional description of HTT is as a “scaffolding protein.”
This is because HTT has many interaction partners and these are involved in a wide variety of
cellular processes, including gene transcription, intracellular signaling, trafficking, endocytosis, and
metabolism (Harjes and Wanker, 2003), hence one might describe HD as a multi-system disorder
(Mielcarek, 2015).
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In humans, HD is characterized by motor dysfunction,
cognitive decline, and a progressive dementia, with the first
symptoms typically occurring in midlife (for review see Zielonka
et al., 2015). Although HD is still being described as a
neurological disorder, there is incontrovertible and growing
evidence that peripheral pathology participates in disease
progression (Mielcarek, 2015). This is in line with the fact that
HTT is normally expressed at high levels in a wide variety of
mammalian tissues (Li et al., 1993). Furthermore, pathological
high molecular weight HTT aggregates have been identified
in many non-central nervous system tissues including skeletal
muscle (Moffitt et al., 2009), although interestingly not in
hearts (Mielcarek et al., 2014a). Aggregation of mutant HTT is
widely-believed to be one of the most important HD molecular
pathology signatures and can be detected at an early pre-
symptomatic stage in both pre-clinical and clinical HD settings
(Davies et al., 1997). HD-related skeletal muscle malfunction
has been widely described in both these settings (reviewed in
Zielonka et al., 2014a; Mielcarek and Isalan, 2015).
Skeletal muscle constitutes up to 40% of body mass and, in
healthy conditions, its function is orchestrated by a balanced
network of intrinsic hypertrophic and atrophic signals that
maintain metabolic homeostasis (Arinze, 2005; Ehrenborg and
Krook, 2009). Any imbalance in these signals may lead to
the impairment of muscle regeneration and, consequently, may
cause a detrimental dysfunction of skeletal muscle, as has
been observed in many chronic diseases (Bassel-Duby and
Olson, 2006; Brooks and Myburgh, 2014). We have recently
described physiological and functional changes in the skeletal
muscles of two well-established HD mouse models, namely
R6/2 and HdhQ150 (Mielcarek et al., 2015). We found that
these symptomatic HDmouse models had substantial alterations
in energy equilibria in various skeletal muscles. This was
accompanied by decreased levels of the phosphocreatine/creatine
ratios, as well as lower ADP and AMP levels. Moreover, the
total pools of the adenine nucleotides were also consistently
depleted. Finally, our previous analysis revealed that the EDL
muscle showed a slower glycolytic flux from exogenous glucose,
as well as less oxidation of glucose (Mielcarek et al., 2015).
In order to underpin our understanding of these metabolic
changes, we performed the current transcriptional signature
study. For comparability, we employed the same HD mouse
model (R6/2) in which we previously described muscle energy
imbalances with alterations of purine nucleotides. Since we
previously showed that purine metabolism is significantly altered
in pre-clinical HD settings (Mielcarek et al., 2015), our current
study exclusively focused on the key transcriptional elements
of this process as these might serve as important molecular
biomarkers for up-coming pre-clinical and clinical studies in HD.
Finally, it should be noted that HD was initially recognized
as neurological disorder; although peripheral pathology was
noticed, it was generally believed that the changes in peripheral
organs were a consequence of CNS degeneration. As a result, over
the past decades, researchers concentrated on identifying HD
biomarkers that are exclusively attributed to CNS degeneration.
However, a number of recently published studies have indicated
that skeletal muscle atrophy might be driven by intrinsic mutant
HTT functions in muscle (for review Zielonka et al., 2015).
Moreover, HD has started to be recognized as a multi-system
disorder (Mielcarek, 2015). Hence, there is an urgent need
to identify biomarkers that will reflect peripheral pathological
changes including those related to HD-skeletal muscle atrophy.
MATERIALS AND METHODS
Mouse Maintenance and Genotyping
The R6/2 HD mouse line was bred and genotyped as previously
described (Mielcarek et al., 2015; Agustín-Pavón et al., 2016).
All experimental procedures were conducted under a project
license from the Home Office, UK and approved by the Animal
Welfare and Ethical Review Body of Imperial College London.
Experimental groups included the R6/2 mouse model at 12
weeks of age (n = 6) and their C57BL/6J littermates (n = 6).
All animals had unlimited access to water and breeding chow
(Special Diet Services, Witham, UK), and housing conditions
and environmental enrichment were as described previously
(Mielcarek et al., 2015; Agustín-Pavón et al., 2016).
RNA Extraction and Taqman Real-Time
PCR Expression Analysis
Total RNA from skeletal muscles was extracted with the
mini-RNA kit (Qiagen, UK), according to the manufacturer’s
instructions. The reverse transcription reaction was performed
using MMLV superscript reverse transcriptase (Invitrogen,
USA) and random hexamers (Sigma, USA), as described in an
earlier study (Mielcarek et al., 2011). All Taqman qPCR reactions
were performed with a LightCycler R© 480 Instrument (Roche), as
described previously (Agustín-Pavón et al., 2016). Following Taq-
man assays from Thermo Fisher Scientific were used in this study
Adsl (Mm_00507759_m1); Adssl1 (Mm_00475814_m1); Gart
(Mm_00599836_m1); Ppat (Mm_00549096_m1);
Aprt (Mm_04207857_g1); Ak1 (Mm_00445475_m1);
Gmpr (Mm_00499393_m1); Impdh2 (Mm_00496156_m1);
Ada (Mm_00545720_m1); Adk (Mm_00612772_m1); Nt5e
(Mm_00501910_m1); Ampd3 (Mm_00477495_m1); Entpd2
(Mm_00515450_m1); Pnp (Mm_00840006_m1); Xdh
(Mm_00442110_m1); Prkaa1 (Mm_01296700_m1);
Pdk4 (Mm_01166879_m1); Hk2 (Mm_00443385_m1).
mRNA copy number was determined in triplicate for each
RNA sample by comparison with the geometric mean of three
endogenous housekeeping genes (Primer Design, UK), as
described (Mielcarek et al., 2011). Stable housekeeping genes
for qPCR profiling of various skeletal muscles for HD mouse
models were determined using the Primer Design geNormTM
Housekeeping Gene Selection Mouse Kit with PerfectProbeTM
software.
Statistical Analysis
Values were presented as mean ± SEM. Statistical analysis was
performed using paired Student t-tests (Excel) or One-Way
Anova SPSS (IBM). A p-value of 0.05 was considered as a
significant difference.
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FIGURE 1 | (A) Summary of composition of fiber types in the hindlimb skeletal muscles used in this study. (B) Identification of reference genes for qPCR from Soleus
RNA from the R6/2 mouse model. GeNorm analysis was used to identify optimal reference genes. Raw crossing threshold (Ct) data for a panel of 12 potential
reference genes from the geNorm kit in WT and R6/2 mice (12 weeks old) from Soleus. ***p < 0.001.
TABLE 1 | Summary of housekeeping genes specific for each muscle type
in the R6/2 HD mouse model used in this study
Skeletal muscle R6/2 mouse model
EDL B2m, Rpl13a, Yhwaz
SOL B2m, Yhwaz, 18S
TA Atp5b, Rpl13a, Yhwaz
G/P Atp5b, Rpl13a, Yhwaz
Genes were selected based on GeNorm analysis to identify optimal reference genes. The
following gene transcripts were examined: Atcb, Actin, beta, cytoplasmic, 11461; Gapdh,
Glyceraldehydes-3-phosphate dehydrogenase, 14433; Ubc, Ubiquitin C, 22190; B2m,
Beta-2-microglobulin, 12010; Ywhaz, Phospholipase A2, 22631; Rpl13a, Ribosomal
protein L13a, 22121; Canx, Calnexin, 12330; Cyc1, Cytochrome c-1, 66445; Sdha,
Succinate dehydrogenase complex, subunit A, 66945; 18S, 18S rRNA, 19791; Eif4A2,
Eukaryotic translation initiation factor 4A2, 13682; Atp5b, ATP synthase subunit, 11947.
Some of the genes used in this study have been previously identified as stable reference
genes (Mielcarek et al., 2015).
RESULTS
In order to establish the transcriptional signature related to the
pathology observed in HD skeletal muscle, we employed the
R6/2 transgenic mouse model of HD, representing the fully
symptomatic stage of a rapid-onset form of the disease. Since
the characteristic energy imbalance was previously detected in all
muscle types, we performed a detailed profiling of transcriptional
changes related to purine metabolism and energy balance within
different muscles. We focused on Extensor Digitus Longum
(EDL), Soleus (Sol), Tibialis Anterior (TA) and Gastrocnemius,
and Plantaris complex (G/P) because these are composed
from metabolically-different muscle fibers. Typically, hindlimb
muscles can be divided into two groups (fast and slow) based
on the composition of fibers, containing up to four myosin
isoforms. Type I fibers are also known as slow twitch fibers and
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they produce ATP through an aerobic metabolic cycle. Type
IIa fibers are also known as intermediate fast oxidative fibers
and they produce ATP through both aerobic and anaerobic
metabolic pathways. Type IIb fibers are known as fast glycolytic
fibers and they produce ATP through an anaerobic metabolic
cycle (Schiaffino and Reggiani, 2011). Figure 1A summarizes
the hindlimb muscle classification used in this study, based
on a previously published study in the C57BL6J mouse strain
(Augusto et al., 2004).
Since HD causes large amount of transcriptional deregulation,
we performed a systematic study to identify suitable reference
genes for use in the expression analysis of different skeletal
muscle types. We previously established a number of
housekeeping genes that are stable across the different muscle
types used in this study, summarized in Table 1 (Mielcarek et al.,
2015). We used the geNormTM Housekeeping Gene Selection
Mouse Kit, and associated software, to identify the three most
stably-expressed genes in Soleus muscles from R6/2 (Figure 1B).
This approach was necessary for our relative quantification
method; this uses the geometric mean of three selected reference
genes for normalization, to accurately determine gene expression
levels in WT and R6/2 skeletal muscle tissue, summarized in
Table 1.
Since we showed previously that purine metabolism is altered
in HD skeletal muscles (Mielcarek et al., 2015), we next studied
the transcriptional signature of genes involved in de novo purine
synthesis. These were examined in different muscles in the R6/2
HD mouse model, using comparisons to control WT littermates.
First, we found that the transcript levels of two genes
involved in the purine nucleotide cycle (PNC) were significantly
down-regulated. Adenylosuccinate lyase (Adsl, Figure 2A) and
Adenylosuccinate lyase 1 (Adlssl1, Figure 2B) were reduced by
∼40–80% in each type of skeletal muscle.
When examining the mRNA levels of enzymes involved in
purine synthesis, we found that Phosphoribosylglycinamide
formyltransferase (Gart) was significantly up-regulated (up
to 2-fold) in each type of skeletal muscle (Figure 2C). In
contrast, Adenine phosphoribosyltransferase (Aprt) and
Amidophosphoribosyltransferase (Ppat) mRNA remained
unchanged (Figures 2D,E).
FIGURE 2 | Transcriptional remodeling of genes involved in de novo purine synthesis and salvage pathway. Transcripts of genes involved in de novo purine
biosynthesis. (A) Adsl, Adenylosuccinate lyase; (B) Adssl1, Adenylosuccinate lyase 1; (C) Gart, Phosphoribosylglycinamide formyltransferase; (D) Ppat,
Amidophosphoribosyltransferase; and the purine nucleotide salvage pathway (E) Aprt, Adenine phosphoribosyltransferase; were assessed in different types of skeletal
muscle: EDL, Extensor Digitorum Longus; SOL, Soleus; TA, Tibialis Anterior; and G/P, Gastrocnemius and Plantaris complex. All Taqman qPCR-values were
normalized to the geometric mean of three housekeeping genes as indicated in the Materials and Methods Section. Error bars are ± SEM (n = 6). Student’s t-test: *p
< 0.05, **p < 0.01; ***p < 0.001.
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We also examined the transcriptional changes of genes
involved in the conversion of purine nucleotides. We found
that mRNA levels of Adenylate kinase 1 (Ak1; an enzyme
that is involved in the catalysis of the terminal phosphate
group between ATP and AMP) were significantly down-
regulated in each type of skeletal muscle examined (Figure 3A).
Conversely, the transcript levels of Inosine monophosphate
dehydrogenase 2 (Impdh2), which catalyzes the conversion
of IMP (Inosine 5′-phosphate) to XMP (Xanthosine 5′-
phosphate), were significantly up-regulated, by up to 2-fold
(Figure 3C). The transcript levels of Guanosine monophosphate
reductase (Gmpr; maintains the intracellular balance of
adenine and guanine nucleotides) remained unchanged
(Figure 3B).
Subsequently, we verified the transcriptional changes of
selected genes that are believed to be involved in adenosine
metabolism. The mRNA levels of Ada (Adenosine deaminase;
Figure 4A), Adk (Adenosine kinase; Figure 4B) and Nt5e (Ecto-
5′-nucelotidase; Figure 4C) remained unchanged under all
conditions.
We next assessed the transcriptional signature of genes
involved in purine metabolism and their degradation. There
was a significant up-regulation of the Ampd3 (Adenosine
monophosphate deaminase 3) specifically in the fast-type muscles
like EDL (Figure 5A). In fact, the effect was large (up to 9-
fold), which is interesting given that Ampd3 is a marker of
skeletal muscle denervation (Fortuin et al., 1996). In addition, we
observed a robust Ampd3 mRNA up-regulation in other muscle
FIGURE 3 | Transcriptional alteration of genes engaged in conversion of adenine nucleotides. Transcripts of (A) Ak1, Adenylate kinase 1; (B) Gmpr,
Guanosine monophosphate reductase; and (C) Impdh2, inosine monophosphate dehydrogenase 2; were assessed in different types of skeletal muscle: EDL,
Extensor Digitorum Longus; SOL, Soleus; TA, Tibialis Anterior; and G/P, Gastrocnemius and Plantaris complex. All Taqman qPCR-values were normalized to the
geometric mean of three housekeeping genes as indicated in the Materials and Methods Section. Error bars are ± SEM (n = 6). Student’s t-test: *p < 0.05, **p <
0.01; ***p < 0.001.
FIGURE 4 | Unchanged transcriptional levels of genes involved in in adenosine metabolism. Transcripts of (A) Ada, Adenosine deaminase; (B) Adk,
Adenosine kinase; and (C) Nt5e, Ecto-5′-nucleotidase; were assessed in different types of skeletal muscle: EDL, Extensor Digitorum Longus; SOL, Soleus; TA, Tibialis
Anterior; and G/P, Gastrocnemius and Plantaris complex. All Taqman qPCR-values were normalized to the geometric mean of three housekeeping genes as indicated
in the Materials and Methods Section. Error bars are ± SEM (n = 6). Student’s t-test: p > 0.05.
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FIGURE 5 | Transcriptional remodeling of genes involved in purine
metabolism and their degradation. Transcript levels of (A) Ampd3,
Adenosine deaminase 3; (B) Entpd2, Ectonucleoside triphosphate
diphosphohydrolase 2; (C) Pnp, Purine nucleoside phosphorylase; (D) Xdh,
Xanthine dehydrogenase; assessed in different types of skeletal muscle: EDL,
Extensor Digitorum Longus; SOL, Soleus; TA, Tibialis Anterior; and G/P,
Gastrocnemius and Plantaris complex. All Taqman qPCR-values were
normalized to the geometric mean of three housekeeping genes as indicated
in the Materials and Methods Section. Error bars are ± SEM (n = 6). Student’s
t-test: *p < 0.05, **p < 0.01; ***p < 0.001.
types like soleus (up to 5-fold), TA (up to 6-fold), and G/P (up to
2.5-fold).
There was a significant down-regulation across tested
conditions of Entpd2 (Ectonucleoside triphosphate
diphosphohydrolase 2; regulates ATP hydrolysis), specifically
in fast-type skeletal muscles, such as EDL (Figure 5B).
Contrastingly, the mRNA levels of Pnp (Purine nucleoside
phosphorylase) were significantly and uniformly up-regulated
across each muscle examined (Figure 5C).
We further validated the expression levels of mRNAs coding
for enzymes involved in purine degradation pathways (Yang
et al., 2008; Walker et al., 2011). We found that Xdh (Xanthine
dehydrogenase) transcript levels were significantly up-regulated,
uniformly across all conditions (Figure 5D).
Finally, we assessed the expression levels of two genes involved
in energy metabolism. Prkaa1 (5′-AMP-activated protein kinase
catalytic subunit alpha-1) mRNA levels were significantly up-
regulated up to 3-fold, in both fast- and slow-type skeletal muscle
(Figure 6A). Similarly, Pdk4 (Pyruvate dehydrogenase, kinase
isozyme 4) transcript levels were found to be up-regulated up
to 6-fold in fast-type muscle (EDL; Figure 6B). The transcript
levels of Hk2 (Hexokinase 2) were significantly down-regulated,
particularly in the fast-type muscles like EDL (Figure 6C). Thus,
one may conclude that there was a significant deregulation
of both these energy metabolism genes, whose function we
previously reported to be deregulated in HD mouse models
(Mielcarek et al., 2015). Overall, the changes in transcript levels in
different muscles in the R6/2 HD mouse model are summarized
in Figure 7.
DISCUSSION
HD is an autosomal dominant, progressive, neurodegenerative
disorder for which there are currently only symptomatic
treatments, reviewed in Zielonka et al. (2015). There is a clear
need to develop disease modifying therapies and the progress
of these can be informed by new insights into the underlying
molecular pathologies. For instance, it is becoming more-and-
more apparent that HD can be described as mitochondriopathy:
multiple studies have described mitochondrial defects, both in
vitro and in vivo, that might play a central role in HD CNS
degeneration (for review see Damiano et al., 2010). Furthermore,
it is emerging that HD has a peripheral component contributing
to its pathology, including skeletal muscle atrophy (Zielonka
et al., 2014a) and heart failure (Zielonka et al., 2014b). In
fact, HD-related cardiomyopathy is characterized by brady-
and tachyar-rhythmias, variations in heart rates and cardiac
remodeling (Mielcarek et al., 2014a), and these are in line
with recently published clinical data (Stephen et al., 2015).
Consequently, it has been shown that these cardiac pathologies
might be caused by significant alterations in mitochondrial
structure, including the loss of mitochondrial elongated shapes
and diffused mitochondrial densities (Mihm et al., 2007; Kiriazis
et al., 2012). Supporting this view of alteredmitochondrial energy
metabolism, we observed an increased level of purine catabolites
in the heart mass of HDmousemodels (Toczek et al., 2016a,b). In
addition, reactive oxygen species (ROS) play an important role in
mitochondrial dysfunction, especially in skeletal muscle atrophy
(Zuo et al., 2015; Zuo and Pannell, 2015) and heart failure (He
and Zuo, 2015). Similarly, ROS overproduction has been linked
to many neurodegenerative diseases (Manoharan et al., 2016),
including HD (Ayala-Peña, 2013). In fact, it has been shown
that mutant HTT aggregation directly leads to increased ROS
production in vitro (Hands et al., 2011).
A mitochondrial dysfunction is also present in HD skeletal
muscle. For example, HD subjects develop a deficit in
mitochondrial oxidative metabolism in skeletal muscles (Saft
et al., 2005). This was shown in muscle cell cultures that
exhibited abnormalities in mitochondrial membrane potential
and cytochrome 3 release (Ciammola et al., 2006). Additionally,
our recently published study in HD pre-clinical settings clearly
identified an energy deficit and altered metabolism of purine
nucleotides, spanning both fast and slow types of skeletal
muscle (Mielcarek et al., 2015). This mechanism underpins
the progressive impairment of the contractile characteristics of
skeletal muscles in HD. In fact, we previously reported that the
pool of ATP, ADP, and NAD+ was depleted in fast (EDL) and
slow (Soleus) types of skeletal muscle, in R6/2 and HdhQ150
mouse models (Mielcarek et al., 2015). Hence, the aim of this
study was to identify a transcriptional signature that is linked
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FIGURE 6 | Transcriptional alteration of genes involved in energy homeostasis. Transcripts of genes involved in (A) Prkaa1, 5′-AMP-activated protein kinase
catalytic subunit alpha-1 and (B) Pdk4, Pyruvate dehydrogenase, kinase isozyme 4; (C) Hk2, Hexokinase 2; were assessed in different types of skeletal muscle: EDL,
Extensor Digitorum Longus; SOL, Soleus; TA, Tibialis Anterior; and G/P, Gastrocnemius and Plantaris complex. All Taqman qPCR-values were normalized to the
geometric mean of three housekeeping genes as indicated in the Materials and Methods Section. Error bars are ± SEM (n = 6). Student’s t-test: **p < 0.01; ***p <
0.001.
FIGURE 7 | Summary of significantly deregulated transcripts in HD skeletal muscles that might alter purine homeostasis, leading to an energy
imbalance. Adsl, Adenylosuccinate lyase; Adssl1, Adenylosuccinate lyase 1; Gart, Phosphoribosylglycinamide formyltransferase; Ak1, Adenylate kinase 1; Impdh2,
inosine monophosphate dehydrogenase 2; Entpd2, Ectonucleoside triphosphate diphosphohydrolase 2; Ampd3, Adenosine deaminase 3; Pnp, Purine nucleoside
phosphorylase; Xdh, Xanthine dehydrogenase; Hk2, Hexokinase 2; Prkaa1; 5′-AMP-activated protein kinase catalytic subunit alpha-1; Pdk4, Pyruvate
dehydrogenase, kinase isozyme 4.
to the observed imbalance in purine metabolism and energy
production, in order to identify a set of novel biomarkers for
HD-related pathology.
A key feature of our study is that we performed our
analysis on different types of skeletal muscle, chosen for their
contrasting fiber compositions. Therefore, we carried out our
transcriptional analysis on EDL (fast-type muscle), Soleus (slow-
type muscle), and TA or G/P (mixed fiber compositions). It
should be emphasized that skeletal muscle atrophy in HD affects
both types of muscles (slow and fast; Sathasivam et al., 1999;
Mielcarek et al., 2015). However, the process of atrophy is
greater in type II fibers (fast), relative to type I (slow; Ribchester
et al., 2004), which in turn may result in a fast-to-slow twitch
conversion.
Muscle atrophy can also alter gene expression and Ampd3 is
believed to be a marker of muscle disuse and muscle denervation
(Fortuin et al., 1996). Interestingly, we found a robust up-
regulation ofAmpd3 transcript levels (up to 9-fold). This is in line
with our previous data, indicating that HDmuscles are becoming
denervated due to loss of motor units function or their inactivity
(Mielcarek et al., 2015).
Moreover, we found changes in gene expression that tie
in to our previous observations of altered metabolism in HD
skeletal muscle (Mielcarek et al., 2015). For example, there was a
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significant up-regulation (up to 3-fold) of genes such as Pnp and
Xdm, which are linked directly to purine metabolism. We also
noticed a significant up-regulation of transcripts that are involved
in energy homeostasis, including Prkaa1 (up to 4-fold) and Pdk4
(up to 6-fold; for a review see Ehrenborg and Krook, 2009). On
the other hand, we found a number of gene transcripts to be
down-regulated and these are linked to de novo purine synthesis,
like Adsl and Adssl1, followed by Entpd2 and Hk2 (both involved
in purine metabolism).
In summary, we report the first transcriptional signature
that represents changes in energy homeostasis and an altered
purine metabolism in the skeletal muscles of an HD mouse
model (Figure 7). We believe that the genes used here might
provide a useful set of HD biomarkers, both for tracking disease
progression and for developing therapies. In fact, there is a
growing interest in including skeletal muscle malfunction as a
therapeutic target to delay disease progression in HD (Mielcarek
et al., 2014b; Zielonka et al., 2014a; Mielcarek, 2015). For
example, it was recently shown that reversing skeletal muscle
malfunction, by blocking the myostatin pathway, extended the
lifespan of the R6/2 mouse model (Mielcarek et al., 2014b).
Additionally, HD skeletal muscle shows a denervation-like
phenotype, which might be linked to the deregulated HDAC4-
myogenin axis (Mielcarek et al., 2015), and HDAC4 is a valid
therapeutic target in HD (Mielcarek et al., 2011, 2013).
Ultimately, lowering levels of mutant Huntingtin in HD
settings is the most widely accepted therapeutic strategy and here
it would be useful to have a set of biomarkers for both central
and peripheral (e.g., skeletal muscle) pathology. In this context,
we recently published an approach based on artificial zinc finger
transcription repressors, targeted to mutant HTT (Garriga-
Canut et al., 2012; Agustín-Pavón et al., 2016). We showed that
a single AAV delivery treatment can repress the mutant gene in
mouse brains for up to 6 months (Agustín-Pavón et al., 2016)
and the treatment has the potential to be extended to HD muscle
therapy. Hence, our panel of newly identified HD-associated
transcripts, which are related to purine metabolism and energy
imbalance, might serve as a biomarker platform in such pre-
clinical settings. Finally, sinceHD-related skeletal muscle atrophy
shares many molecular and physiological mechanisms with
muscle cachexia in cancer mouse models (Mielcarek and Isalan,
2015), it is likely that our set of transcriptional biomarkers may
have even wider applications in these settings.
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